日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

针对 CC 趋化因子配体 2 (CCL2) 的人类单克隆抗体 carlumab (CNTO 888) 治疗转移性去势抵抗性前列腺癌的 2 期研究

Kenneth J Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J Crabb, Susan Li, Shobha Seetharam, Thomas A Puchalski, Chris Takimoto, Yusri Elsayed, Fitzroy Dawkins, Johann S de Bono

A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

细胞重定向双特异性 G 蛋白偶联受体 5 类成员 D x CD3 抗体用于治疗多发性骨髓瘤

Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonça, Yingzhe Li, Mark Tornetta, Alexander Babich, Nate Majewski, Matt Husovsky, Dara Reeves, Eileen Walsh, Diana Chin, Leopoldo Luistro, Jocelin Joseph, Gerald Chu, Kathryn Packman, Shoba Shetty, Yusri Elsayed, Ricardo Attar, François Gaudet